Merck and Moderna report melanoma vaccine breakthrough, stocks surge

Merck and Moderna announced progress in developing an mRNA vaccine against melanoma, designed to prevent the cancer's return and spread in high-risk patients. The announcement triggered a significant rise in share prices for both companies on the New York Stock Exchange. The results could pave the way for regulatory approval.